SCHEMBL582152

SCHEMBL582152

CC(Cn1ccc2cc(Br)ccc2c1=O)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.46
HTR2C P28335 2/20 0.46
PSMB1 P20618 3/20 0.41
PSMB5 P28074 3/20 0.41
DPP4 P27487 1/20 0.41
GRM4 Q14833 1/20 0.37
NTSR1 P30989 1/20 0.37
HSP90AB1 P08238 1/20 0.37
DAO P14920 1/20 0.36
KDM4E B2RXH2 1/20 0.36
POLB P06746 1/20 0.36
GRM2 Q14416 1/20 0.36
SRC P12931 2/20 0.35
ABL1 P00519 1/20 0.35
TDP2 O95551 1/20 0.35
CDC25B P30305 1/20 0.35
CASP6 P55212 1/20 0.35
PPP1CA P62136 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20786917 0.84 HTR2A (0.52) HTR2AHTR2CPSMB1PSMB5DPP4
SCHEMBL2627971 0.81 PSMB1 (0.39) HTR2AHTR2CPSMB1PSMB5GRM4
SCHEMBL1500397 0.78 HTR2C (0.46) HTR2AHTR2CPSMB1PSMB5DPP4
SCHEMBL2124366 0.77 DPP4 (0.39) HTR2AHTR2CDPP4POLBTDP2
SCHEMBL2120980 0.77 MAPK14 (0.48) HSP90AB1MEN1KMT2A
SCHEMBL1500208 0.76 PSMB1 (0.43) HTR2AHTR2CPSMB1PSMB5NTSR1
SCHEMBL582811 0.75 HSP90AB1 (0.61) HSP90AB1KDM4EGRM2
SCHEMBL2122301 0.74 APLNR (0.37) DPP4TDP2CDC25BCASP6PPP1CA
SCHEMBL6923560 0.74 GRM2 (0.55) HTR2AHTR2CPSMB1PSMB5HSP90AB1
SCHEMBL1500297 0.73 HTR2A (0.39) HTR2AHTR2CPSMB1PSMB5DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8802064-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2014-08-12 US disclosed
EP-2416660-B1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS INC (US) 2014-07-02 EP disclosed
US-20130345173-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2013-12-26 US disclosed
US-8546564-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2013-10-01 US disclosed
US-20120094957-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS INC. 2012-04-19 US disclosed
EP-2416660-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE Infinity Pharmaceuticals, Inc. (US) 2012-02-15 EP disclosed
WO-2010118155-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130345173-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, FFAR3 HTR2A 691/4885HTR2C 617/4885PSMB1 2054/4885
US-20120094957-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, FFAR3 HTR2A 784/4885HTR2C 684/4885PSMB1 2090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.